GlassScriptPhysician profile
Aaron G Ellison
NPI 1730154659
$14,435.12
in general payments reported to CMS, 2019-2025
57 companies · $968 in 2025
The $968 reported for 2025 was more than what 89% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,641 · 2020: $2,195 · 2021: $2,937 · 2022: $2,619 · 2023: $1,746 · 2024: $1,329 · 2025: $968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,990 · Education: $52.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,989.54 |
| Education | $52.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,168.02 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,630.11 | 2019-2025 | |
| Novo Nordisk INC | $1,574.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,086.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,056.54 | 2019-2025 | Ofev, Jardiance, Cyltezo |
| Pfizer INC. | $879.85 | 2019-2025 | |
| Glaxosmithkline, LLC. | $717.96 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $640.14 | 2019-2024 | Belsomra, Steglatro, Gardasil |
| Sunovion Pharmaceuticals INC. | $487.87 | 2019-2022 | |
| Amgen INC. | $386.61 | 2019-2024 | Otezla, Repatha, Prolia |
| Janssen Pharmaceuticals, INC | $382.64 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $302.81 | 2021-2025 | |
| Abbott Laboratories | $243.75 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $241.60 | 2019-2023 | Xifaxan |
| Amarin Pharma, INC. | $198.55 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Ellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.